| MeSH term | MeSH ID | Detail |
|---|---|---|
| Cutaneous Fistula | D017577 | 1 associated lipids |
| Kleine-Levin Syndrome | D017593 | 1 associated lipids |
| Periodontal Attachment Loss | D017622 | 7 associated lipids |
| Soft Tissue Injuries | D017695 | 2 associated lipids |
| Community-Acquired Infections | D017714 | 8 associated lipids |
| Cytomegalovirus Retinitis | D017726 | 2 associated lipids |
| Tuberculosis, Multidrug-Resistant | D018088 | 6 associated lipids |
| Cardiovascular Abnormalities | D018376 | 2 associated lipids |
| Pneumonia, Bacterial | D018410 | 16 associated lipids |
| Soft Tissue Infections | D018461 | 2 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Zullo A et al. | A new highly effective short-term therapy schedule for Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848654 |
| Ikeda S et al. | Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan. | 2001 | Aliment. Pharmacol. Ther. | pmid:11683692 |
| Moayyedi P et al. | The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848655 |
| Katelaris PH et al. | Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848659 |
| Ammon S et al. | Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848660 |
| Leiper K et al. | Open label trial of oral clarithromycin in active Crohn's disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848665 |
| Sharara AI et al. | Letter: clarithromycin dose for H. pylori therapy remains unresolved--authors' reply. | 2015 | Aliment. Pharmacol. Ther. | pmid:26238584 |
| Graham DY and Gisbert JP | Letter: clarithromycin dose for H. pylori therapy remains unresolved. | 2015 | Aliment. Pharmacol. Ther. | pmid:26238583 |
| Wheeldon TU et al. | The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication. | 2004 | Aliment. Pharmacol. Ther. | pmid:15191514 |
| Kositchaiwat C et al. | Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:14616168 |
| Romero-Gómez M et al. | Three-day intravenous triple therapy is not effective for the eradication of Helicobacter pylori infection in patients with bleeding gastro-duodenal ulcer. | 2003 | Aliment. Pharmacol. Ther. | pmid:14616169 |
| Datta S et al. | Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. | 2005 | Aliment. Pharmacol. Ther. | pmid:15963080 |
| Fischbach L and Evans EL | Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. | 2007 | Aliment. Pharmacol. Ther. | pmid:17635369 |
| Thijs JC et al. | Short report: clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection. | 1994 | Aliment. Pharmacol. Ther. | pmid:8186339 |
| Murakami K et al. | Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. | 2002 | Aliment. Pharmacol. Ther. | pmid:12390102 |
| Gisbert JP et al. | 7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure. | 2005 | Aliment. Pharmacol. Ther. | pmid:15882246 |
| Nista EC et al. | Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. | 2005 | Aliment. Pharmacol. Ther. | pmid:15882245 |
| Lamouliatte H et al. | Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535872 |
| Gisbert JP and Calvet X | Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. | 2012 | Aliment. Pharmacol. Ther. | pmid:22129228 |
| Bühling A et al. | Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. | 2001 | Aliment. Pharmacol. Ther. | pmid:11552917 |
| Dani R et al. | Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. | 1999 | Aliment. Pharmacol. Ther. | pmid:10594400 |
| Boixeda D et al. | Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection. | 2002 | Aliment. Pharmacol. Ther. | pmid:12182745 |
| Bruley Des Varannes S et al. | There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. | 2001 | Aliment. Pharmacol. Ther. | pmid:11472320 |
| Adachi K et al. | Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. | 2001 | Aliment. Pharmacol. Ther. | pmid:11472321 |
| Sierra F et al. | Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. | 2013 | Aliment. Pharmacol. Ther. | pmid:23656465 |
| Bardhan KD et al. | Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori. | 2001 | Aliment. Pharmacol. Ther. | pmid:11472323 |
| Masaoka T et al. | Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. | 2004 | Aliment. Pharmacol. Ther. | pmid:15298608 |
| Kondo Y et al. | Helicobacter pylori eradication decreases blood neutrophil and monocyte counts. | 2004 | Aliment. Pharmacol. Ther. | pmid:15298609 |
| Gschwantler M et al. | Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468682 |
| Paré P et al. | Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468683 |
| Sung JJ et al. | One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468684 |
| Lehmann FS et al. | Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10735923 |
| Miwa H et al. | Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10735925 |
| Spinzi GC et al. | Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10735926 |
| Di Mario F et al. | Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. | 2006 | Aliment. Pharmacol. Ther. | pmid:16611285 |
| Madisch A et al. | Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. | 2006 | Aliment. Pharmacol. Ther. | pmid:16441467 |
| Graham DY et al. | Furazolidone combination therapies for Helicobacter pylori infection in the United States. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651662 |
| Borody TJ et al. | Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. | 2006 | Aliment. Pharmacol. Ther. | pmid:16441468 |
| Laine L | Review article: esomeprazole in the treatment of Helicobacter pylori. | 2002 | Aliment. Pharmacol. Ther. | pmid:12047270 |
| Sung JJ et al. | One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9726384 |
| Pazzi P et al. | Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. | 1998 | Aliment. Pharmacol. Ther. | pmid:9726385 |
| Harris AW et al. | Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group. | 1998 | Aliment. Pharmacol. Ther. | pmid:9726387 |
| Malfertheiner P et al. | Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. | 2003 | Aliment. Pharmacol. Ther. | pmid:12969088 |
| Hassan C et al. | Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. | 2003 | Aliment. Pharmacol. Ther. | pmid:12969091 |
| Vakil N et al. | Duplicate breath testing to confirm eradication of Helicobacter pylori: incremental benefit and cost in 419 patients. | 2008 | Aliment. Pharmacol. Ther. | pmid:18774949 |
| Shokri-Shirvani J et al. | Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. | 2016 | Aliment. Pharmacol. Ther. | pmid:27137738 |
| Ricciardiello L et al. | Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678812 |
| Cammarota G et al. | One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678813 |
| Louw JA et al. | Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678814 |
| Ahuja V et al. | Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678815 |
| Grübel P and Cave DR | Factors affecting solubility and penetration of clarithromycin through gastric mucus. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678818 |
| Malfertheiner P et al. | Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. | 2002 | Aliment. Pharmacol. Ther. | pmid:11860399 |
| Huang J and Hunt RH | The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383500 |
| Miwa H et al. | Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383502 |
| Ducóns JA et al. | Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383507 |
| Calvet X et al. | Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383508 |
| Vakil N et al. | Seven-day therapy for Helicobacter pylori in the United States. | 2004 | Aliment. Pharmacol. Ther. | pmid:15225176 |
| Wong BC et al. | Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. | 2001 | Aliment. Pharmacol. Ther. | pmid:11736727 |
| Kashimura H et al. | Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215732 |
| Lee JM et al. | Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215733 |
| Neville PM et al. | The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215734 |
| Hoffman JS et al. | Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215735 |
| Gisbert JP et al. | Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy. | 2000 | Aliment. Pharmacol. Ther. | pmid:10971230 |
| Frevel M et al. | Eradication of Helicobacter pylori with pantoprazole and two antibiotics: a comparison of two short-term regimens. | 2000 | Aliment. Pharmacol. Ther. | pmid:10971231 |
| Bigard MA et al. | One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. | 1998 | Aliment. Pharmacol. Ther. | pmid:9690730 |
| Tam YH et al. | Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study. | 2006 | Aliment. Pharmacol. Ther. | pmid:16803605 |
| Bardhan KD et al. | Pantoprazole-based 10-day triple therapy is effective in Helicobacter pylori eradication. | 1998 | Aliment. Pharmacol. Ther. | pmid:9692693 |
| Sengupta S et al. | Effect of oral clarithromycin on gall-bladder motility in normal subjects and those with gall-stones. | 2006 | Aliment. Pharmacol. Ther. | pmid:16803607 |
| Catalano F et al. | Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9692702 |
| Dobrilla G et al. | Ranitidine bismuth citrate with either clarithromycin 1 g/day or 1.5 g/day is equally effective in the eradication of H. pylori and healing of duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9692703 |
| Ford AC et al. | Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. | 2007 | Aliment. Pharmacol. Ther. | pmid:17944741 |
| Perri F et al. | Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535875 |
| Laine L et al. | A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354200 |
| Rinaldi V et al. | The management of failed dual or triple therapy for Helicobacter pylori eradication. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354202 |
| Breuer T et al. | Clarithromycin, amoxycillin and H2-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354204 |
| Wurzer H et al. | Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354205 |
| Harris A | H. pylori eradication by LAC. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354216 |
| Jung YS et al. | Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. | 2017 | Aliment. Pharmacol. Ther. | pmid:28497487 |
| Savarino V et al. | A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. | 1997 | Aliment. Pharmacol. Ther. | pmid:9305478 |
| Yousfi MM et al. | Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy). | 1996 | Aliment. Pharmacol. Ther. | pmid:8871452 |
| Williams MP et al. | Seven-day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride. | 1997 | Aliment. Pharmacol. Ther. | pmid:9305479 |
| Broutet N et al. | Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. | 2003 | Aliment. Pharmacol. Ther. | pmid:12492738 |
| Chi CH et al. | Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. | 2003 | Aliment. Pharmacol. Ther. | pmid:12895220 |
| Higuchi K et al. | Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. | 2003 | Aliment. Pharmacol. Ther. | pmid:12492739 |
| Peterson WL et al. | Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group. | 1996 | Aliment. Pharmacol. Ther. | pmid:8791947 |
| Delchier JC et al. | Omeprazole-amoxycillin versus omeprazole-amoxycillin-clarithromycin in the eradication of Helicobacter pylori. | 1996 | Aliment. Pharmacol. Ther. | pmid:8791948 |
| Jaup BH and Norrby A | Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8791950 |
| Ott EA et al. | Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. | 2005 | Aliment. Pharmacol. Ther. | pmid:15882244 |
| Weldon MJ et al. | A seven-day Helicobacter pylori treatment regimen using clarithromycin, omeprazole and tripotassium dicitrato bismuthate. | 1996 | Aliment. Pharmacol. Ther. | pmid:8791951 |
| Tursi A et al. | Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8791952 |
| Gisbert JP et al. | Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. | 2012 | Aliment. Pharmacol. Ther. | pmid:22372560 |
| Moshkowitz M et al. | One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971304 |
| Laine L et al. | Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971306 |
| Chen PY et al. | Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28074519 |
| Gisbert JP and Pajares JM | Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. | 2002 | Aliment. Pharmacol. Ther. | pmid:12030945 |
| Zamani M et al. | Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection. | 2017 | Aliment. Pharmacol. Ther. | pmid:28074507 |
| Laine L and Dhir V | Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:12030957 |
| Vallve M et al. | Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. | 2002 | Aliment. Pharmacol. Ther. | pmid:12030958 |
| McNulty CA et al. | Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? | 2012 | Aliment. Pharmacol. Ther. | pmid:22469191 |
| Colin R | Duodenal ulcer healing with 1-week eradication triple therapy followed, or not, by anti-secretory treatment: a multicentre double-blind placebo-controlled trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:12030959 |